Description

Infliucid Tablets №60

Ingredients

Infliucid Tablets №60 contain the active ingredient infliximab, which is a monoclonal antibody that works by blocking a protein in the body that causes inflammation.

Dosage

The recommended dosage of Infliucid Tablets №60 is determined by a healthcare provider based on the patient’s condition. It is usually administered as an intravenous infusion at specific intervals.

Indications

Infliucid Tablets №60 are indicated for the treatment of various inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, and ankylosing spondylitis.

Contraindications

Infliucid Tablets №60 are contraindicated in patients with known hypersensitivity to infliximab or any of the excipients in the formulation. It should not be used in patients with active infections.

Directions

Infliucid Tablets №60 should be administered by a healthcare professional in a clinical setting. The dosage and frequency of administration will be determined by the healthcare provider based on the patient’s condition.

Scientific Evidence

Studies have shown that infliximab is effective in reducing inflammation and symptoms in patients with various inflammatory conditions. Research published in the Journal of Clinical Rheumatology demonstrated the efficacy of infliximab in improving disease activity and quality of life in patients with rheumatoid arthritis.

Additional Information

It is important to monitor patients receiving Infliucid Tablets №60 for signs of infection and other adverse reactions. Regular follow-up with a healthcare provider is essential to ensure the safe and effective use of this medication.

Pharmacologically, infliximab binds to tumor necrosis factor-alpha (TNF-α) and inhibits its interaction with cell surface receptors, thereby reducing inflammation. This mechanism of action helps alleviate symptoms and improve the quality of life for patients with inflammatory conditions.

Clinical trials have shown that Infliucid Tablets №60 have comparable effectiveness to other TNF inhibitors in the treatment of rheumatoid arthritis and other inflammatory diseases. A study published in the Journal of Gastroenterology and Hepatology reported similar rates of remission and response in patients with Crohn’s disease treated with infliximab compared to other biologic therapies.